BCAL Diagnostics (ASX:BDX) Insider Purchases A$19,935.31 in Stock

BCAL Diagnostics Limited (ASX:BDX) insider Jayne Shaw acquired 306,697 shares of the stock in a transaction on Tuesday, September 2nd. The shares were acquired at an average price of A$0.07 per share, with a total value of A$19,935.31.

BCAL Diagnostics Price Performance

The stock has a market cap of $36.60 million, a PE ratio of -4.08 and a beta of 0.69. The company has a debt-to-equity ratio of 17.74, a current ratio of 3.60 and a quick ratio of 6.70.

BCAL Diagnostics Company Profile

BCAL Diagnostics Limited, a screening and diagnostic company, engages in developing a non-invasive blood test for the detection of breast cancer. It develops BCAL test, a lipid biomarker blood test with the potential to be used for breast cancer prevention, screening, and monitoring; and in vitro diagnostic test (IVD) that confirms a fingerprint of lipid biomarkers extracted from patient's blood plasma to diagnose the presence of breast cancer cells in a patient's body.